Sugi Predict

Sugi Predict / Compounds / SCHEMBL2465897

SCHEMBL2465897

SCHEMBL2465897

CC1(O)CC(C2=C3C=NC=C[N+]3(Cl)C(c3cccc(OCc4ccccc4)c3)=N2)C1

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ F9 P00740 1/20 0.34
▸ F10 P00742 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ MAOB P27338 2/20 0.33
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ ADAM17 P78536 2/20 0.33
▸ FAAH O00519 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ IGF1R P08069 2/20 0.33
▸ TNK2 Q07912 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ ERN1 O75460 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459447 0.92 PDE10A (0.33) F9F10NR1H2BRD4CREBBP
SCHEMBL2464664 0.91 CYP4F2 (0.34) F9F10NR1H2PDE10AMRGPRX4
SCHEMBL2459675 0.90 F9 (0.36) F9F10BRD4CREBBPPDE10A
SCHEMBL2464620 0.88 BTK (0.32) F9F10NR1H2PDE10AMRGPRX4
SCHEMBL2463346 0.87 IGF1R (0.35) F9F10NR1H2PDE10AMRGPRX4
SCHEMBL2460207 0.86 NR1H2 (0.35) F9F10NR1H2BRD4CREBBP
SCHEMBL2459426 0.86 BRD4 (0.36) NR1H2BRD4CREBBPPDE10AMAOB
SCHEMBL2463487 0.85 PRMT5 (0.38) IGF1RALOX5
SCHEMBL2460301 0.85 IGF1R (0.35) NR1H2PDE10AMAOBIGF1RALOX5
SCHEMBL2460369 0.85 IGF1R (0.38) NR1H2PDE10AMRGPRX4IGF1RTNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 — — EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 — — US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 — — US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 — — US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 F9 4236/4885F10 3668/4885NR1H2 2603/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 F9 4236/4885F10 3668/4885NR1H2 2603/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 F9 4236/4885F10 3668/4885NR1H2 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.